Simone Schadt

Minimizing DILI risk in drug discovery — A screening tool for drug candidates

Simone Schadt, Silke Simon, Stefan Kustermann et al. · Toxicology in Vitro · 2015 · 88 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

Abyssomicin Biosynthesis: Formation of an Unusual Polyketide, Antibiotic‐Feeding Studies and Genetic Analysis

Elvira Gottardi, Joanna M. Krawczyk, Hanna von Suchodoletz et al. · ChemBioChem · 2011 · 72 citations · Full text

Life Sciences, Biochemistry, Microbiology +9

Identification of GalNAc-Conjugated Antisense Oligonucleotide Metabolites Using an Untargeted and Generic Approach Based on High Resolution Mass Spectrometry

Christophe Husser, Andreas Brink, M. Zell et al. · Analytical Chemistry · 2017 · 57 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges

Simone Schadt, Simon Hauri, Filipe Lopes et al. · Drug Metabolism and Disposition · 2019 · 45 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design

Andreas Brink, Axel Pähler, Christoph Funk et al. · Drug Discovery Today · 2016 · 40 citations

Medicine, Medicinal Chemistry, Pharmacology +16